Recoverin: A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: RCVRN

NCBI ID: G5957

RCVRN

Recoverin: A Potential Drug Target and Biomarker for Neurological Disorders

Recoverin, a protein that is expressed in the brain and other tissues, has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders. The protein is involved in the recovery process following brain injury, and its levels have been shown to be decreased in individuals with certain neurological conditions. This article will explore the potential benefits of recoverin as a drug target and biomarker, as well as its current status in the scientific community.

Potential Drug Target

Recoverin has been shown to have a variety of potential drug targets. One of the most promising targets is the protein known as TrkB. TrkB is a key transcription factor that is involved in the recovery process following brain injury. Studies have shown that TrkB is downregulated in individuals with certain neurological conditions, such as Alzheimer's disease and Parkinson's disease. By targeting TrkB, researchers hope to encourage the production of recoverin and potentially slow the progression of these conditions.

Another potential drug target for recoverin is the protein known as calbindin. Calbindin is a protein that is involved in the regulation of pain and inflammation. Studies have shown that individuals with certain neurological conditions, such as multiple sclerosis and rheumatoid arthritis, have lower levels of calbindin than healthy individuals. By targeting calbindin, researchers hope to reduce inflammation and improve the recovery process in individuals with these conditions.

Biomarker

Recoverin has also been identified as a potential biomarker for various neurological and psychiatric disorders. The protein is involved in the recovery process following brain injury, which makes it an attractive candidate for use as a biomarker for these conditions. For example, individuals with traumatic brain injury (TBI) often experience long-lasting cognitive and behavioral changes. Studies have shown that recoverin levels are decreased in individuals with TBI, which suggests that the protein may be a useful biomarker for this condition.

In addition to its potential as a drug target and biomarker, recoverin is also of interest to researchers because of its role in the central nervous system. The protein is involved in the regulation of a variety of neural processes, including movement, learning, and memory. This makes it an attractive candidate for use as a target for drugs that are designed to modulate these processes.

Current Status

Recoverin is a protein that is expressed in a variety of tissues, including the brain, heart, and kidneys. Studies have shown that recoverin levels are decreased in individuals with certain neurological conditions, such as TBI and Alzheimer's disease. This suggests that recoverin may be a promising candidate for use as a drug target or biomarker for these conditions.

In addition to its potential drug and biomarker potential, recoverin is also of interest to researchers because of its role in the regulation of the immune system. The protein is involved in the regulation of T cells, which are a critical part of the immune system. This makes it an attractive candidate for use as a target for drugs that are designed to modulate the immune system.

Conclusion

Recoverin is a protein that has been identified as a potential drug target and biomarker for a variety of neurological and psychiatric disorders. Its involvement in the recovery process following brain injury makes it an attractive candidate for use as a drug target. In addition, the protein is also of interest to researchers because of its role in the regulation of pain and inflammation. Further research is needed to fully understand the potential benefits and risks of recoverin as a drug target and biomarker.

Protein Name: Recoverin

Functions: Acts as a calcium sensor and regulates phototransduction of cone and rod photoreceptor cells (By similarity). Modulates light sensitivity of cone photoreceptor in dark and dim conditions (By similarity). In response to high Ca(2+) levels induced by low light levels, prolongs RHO/rhodopsin activation in rod photoreceptor cells by binding to and inhibiting GRK1-mediated phosphorylation of RHO/rhodopsin (By similarity). Plays a role in scotopic vision/enhances vision in dim light by enhancing signal transfer between rod photoreceptors and rod bipolar cells (By similarity). Improves rod photoreceptor sensitivity in dim light and mediates response of rod photoreceptors to facilitate detection of change and motion in bright light (By similarity)

The "RCVRN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RCVRN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets